Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhEPO in ALS
NCT03835507Phase 2Recruiting
- Sponsor
- Hanyang University
- Start
- Jun 2016
- Primary completion
- Dec 2020
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of epoetin alfa in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Hanyang University. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 15 months. Started Jun 2016; status: recruiting.
02
Drugs
epoetin alfa
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03835507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835507.